



**Oncoinvent AS**

Gullhaugveien 7  
N-0484 Oslo, Norway

Tlf: (+47) 22 18 33 05  
oncoinvent@oncoinvent.com  
Org. nr. 995764458  
www.oncoinvent.com

**Press Release 07.2018**

**Oncoinvent to present and attend the  
32nd Annual Congress of the  
European Association of Nuclear  
Medicine**

Oslo 12. October 2018

Oncoinvent announces that Radspherin<sup>®</sup> research findings will be presented at the 32nd Annual Congress of the European Association of Nuclear Medicine (EANM) (13-17 October 2018, Düsseldorf, Germany).

The presentation is entitled:  
Alpha-Emitting Radiopharmaceutical for IP Therapy of  
Peritoneal Metastases: In Vitro Evaluation and Therapeutic  
Effects in a Murine Model

Authors: T. B. Bønsdorff, E. Napoli, I. S. Jorstad, S. Westrøm,  
Ø. S. Bruland, R. H. Larsen

Session: EP-55 - Preclinical and translational aspects,  
including radiopharmacy, radiochemistry and drug  
development - Preclinical and translational aspects -  
Preclinical aspects - Animal models and in-vitro studies

Abstract No.: EP-0788

Format: Electronic poster

**About Radspherin<sup>®</sup>**

Radspherin<sup>®</sup> is a novel alpha-emitting radioactive microsphere designed for treatment of metastatic cancers in body cavities. The radium-224 based therapeutic, Radspherin<sup>®</sup> has shown strong and consistent anticancer activity at doses being essentially non-toxic in preclinical studies. It is anticipated that the product can potentially treat several forms of metastatic cancer. The first clinical indication for Radspherin<sup>®</sup> will be



treatment of peritoneal carcinomatosis originating from ovarian cancer. Peritoneal carcinomatosis is one of the most serious complications of gastrointestinal and gynecological malignancies.

### **About Oncoinvent**

Oncoinvent AS is a privately held Norwegian company based in Oslo, Norway. The company is committed to developing new innovative products to provide better treatment options to cancer patients. The company's founders started Oncoinvent in 2010 with a view to designing better cancer treatments by applying known physical and chemical principles of selected novel materials in new ways to maximize their medical benefit while minimizing potential safety concerns. This approach has allowed the company to explore and develop multiple technological avenues before selecting a lead product candidate for preclinical testing.

#### **For further information, please contact:**

Jan A. Alfheim, Chief Executive Officer

Cell: +47 46 44 00 45

Email: [Alfheim@oncoinvent.com](mailto:Alfheim@oncoinvent.com)

IR enquiries:

Ole Peter Nordby, Chief Financial Officer

Cell: +47 41 28 71 79

Email: [nordby@oncoinvent.com](mailto:nordby@oncoinvent.com)